15 December 2006

Total Voting Rights and Share Capital

In conformity with the Transparency Directive's transitional provision 6, Cyprotex is required to notify the market of the following:

The issued share capital of Cyprotex consists of 138,573,016 ordinary shares with a nominal value of 0.1 pence each, with voting rights. Cyprotex does not hold any ordinary shares in Treasury.

Therefore, the total number of voting rights in Cyprotex is 138,573,016.

The above figure of 138,573,016 shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Cyprotex under the Financial Service Authority's Disclosure and Transparency Rules.

Name of contact and telephone number for enquiries:

Mark C. Warburton, Cyprotex Plc Company Secretary: +44 1625 505100

For further information:

Cyprotex PLC
Robert Morrison Atwater, CEO
Tel: +44 1625 505 100
ir@cyprotex.com
www.cyprotex.com

Nomura Code Securities Limited
Charles Walker
Tel: +44 (0)20 7776 1200
cew@nomuracode.com
www.nomuracode.com

Media Enquires:

WMC Communications
Charlie Geller/Alex Glover
Tel: +44 (0)20 7930 9030
charlie.geller@wmccommunications.com